pegcetacoplan: FDA status

Approved Approved Jul 29, 2025. Indication: reduction of proteinuria in C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

Regulatory history

All products in the FDA Tracker

Loading today's edition…